Travere Therapeutics: Positive Topline Interim Results in Phase 3 Sparsentan Study

 Sparsentan treatment group experienced 49.8 percent mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator; interim primary efficacy endpoint achieved, p<0.0001

To date in the study, sparsentan has been generally well-tolerated and consistent with the previously observed safety profile

Submission of an NDA under Subpart H accelerated approval pathway in the U.S. expected in first half 2022

Company to host conference call and webcast today at 8:30 a.m. ET

Travere Therapeutics will host a conference call and webcast today, Monday, August 16, 2021, at 8:30 a.m. ET to discuss the study results. To participate in the conference call, dial +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International), confirmation code 9558913 shortly before 8:30 a.m. ET. The webcast can be accessed at travere.com, in the Events and Presentations section of the Investors & Media page and will be archived for at least 30 days. A replay of the call will be available from 11:30 a.m. ET, August 16, 2021, to 11:30 a.m. ET, August 23, 2021. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 9558913.

https://finance.yahoo.com/news/travere-therapeutics-announces-positive-topline-110000690.html